Abstract
Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.
Keywords: Autoimmune disease, glial activation, neuroinflammation, neurodegeneration, prolyl oligopeptidase, POP, Antigen presenting cells, Bradykinin, Renin-angiotensin system, Ac-SDKP, COPD, Bronchiolitis Obliterans Syndrome, Rheumatoid Arthritis, Mycobacterium tuberculosis, Systemic Lupus Erythematosus
CNS & Neurological Disorders - Drug Targets
Title: Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
Volume: 10 Issue: 3
Author(s): Anne Penttinen, Jofre Tenorio-Laranga, Anssi Siikanen, Markus Morawski, Steffen Roßner and J. Arturo Garcia-Horsman
Affiliation:
Keywords: Autoimmune disease, glial activation, neuroinflammation, neurodegeneration, prolyl oligopeptidase, POP, Antigen presenting cells, Bradykinin, Renin-angiotensin system, Ac-SDKP, COPD, Bronchiolitis Obliterans Syndrome, Rheumatoid Arthritis, Mycobacterium tuberculosis, Systemic Lupus Erythematosus
Abstract: Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.
Export Options
About this article
Cite this article as:
Penttinen Anne, Tenorio-Laranga Jofre, Siikanen Anssi, Morawski Markus, Roßner Steffen and Arturo Garcia-Horsman J., Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653742
DOI https://dx.doi.org/10.2174/187152711794653742 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Renal Blood Flow Dynamics in Inbred Rat Strains Provides Insight into Autoregulation
Current Vascular Pharmacology The Application of Chitosan and Its Derivatives as Nanosized Carriers for the Delivery of Chemical Drugs and Genes or Proteins
Current Drug Targets Snake Venom Phospholipases A2: A Novel Tool Against Bacterial Diseases
Current Medicinal Chemistry The Promises and Challenges of the Use of Genomics in the Prescription of Exercise for Hypertension: The 2013 Update
Current Hypertension Reviews Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design New Highly Potent and Selective Adenosine A3 Receptor Antagonists
Current Topics in Medicinal Chemistry Levosimendan Preoperative
Current Pharmaceutical Design Organic Toxins as Tools to Understand Ion Channel Mechanisms and Structure
Current Topics in Medicinal Chemistry Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals
Current Pharmaceutical Design The Key Role of Medullary 5-HT3 Receptors in the Serotonin-Mediated Neural Control of Cardiovascular Function
Current Neuropharmacology Oligonucleotide-based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs
Current Drug Targets Dopamine: Agonists and Neurodegenerative Disorders
Current Drug Targets Effects of Kallistatin on Oxidative Stress and Inflammation on Renal Ischemia-Reperfusion Injury in Mice
Current Vascular Pharmacology Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications
Current Medicinal Chemistry Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug Safety The Reno-Protective Effect of the Dual Blockade of the Renin Angiotensin System (RAS)
Current Pharmaceutical Design Protective Effects of Curcumin against Lipopolysaccharide-Induced Toxicity
Current Medicinal Chemistry